Skip to main content Skip to footer
HomeHome
 
  • Accueil
  • Recherche de brevets

    Connaissances des brevets

    Accéder à nos bases de données brevets et à nos outils de recherche.

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • Informations techniques
      • Vue d'ensemble
      • Espacenet - recherche de brevets
      • Serveur de publication européen
      • Recherche EP en texte intégral
    • Informations juridiques
      • Vue d'ensemble
      • Registre européen des brevets
      • Bulletin européen des brevets
      • Plan du site de l'Identifiant européen de la jurisprudence
      • Observations de tiers
    • Informations commerciales
      • Vue d'ensemble
      • PATSTAT
      • IPscore
      • Rapports d’analyse sur les technologies
    • Données
      • Vue d'ensemble
      • Technology Intelligence Platform
      • Données liées ouvertes EP
      • Jeux de données de masse
      • Services Internet
      • Couverture, codes et statistiques
    • Plateformes technologiques
      • Vue d'ensemble
      • Le plastique en pleine mutation
      • Innovation autour de l'eau
      • Innovation spatiale
      • Des technologies pour lutter contre le cancer
      • Technologies de lutte contre les incendies
      • Technologies énergétiques propres
      • Lutte contre le coronavirus
    • Ressources utiles
      • Vue d'ensemble
      • Il s'agit de votre première visite ? Qu'est-ce que l'information brevets ?
      • Information brevets de l'Asie
      • Centres d'information brevets (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Commerce et statistiques
      • Informations relatives au brevet unitaire pour la connaissance des brevets
    Image
    Plastics in Transition

    Rapport d’analyse sur les technologies de gestion des déchets plastiques

  • Demander un brevet

    Demander un brevet

    Informations pratiques concernant les procédures de dépôt et de délivrance.

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • Voie européenne
      • Vue d'ensemble
      • Guide du brevet européen
      • Oppositions
      • Procédure orale
      • Recours
      • Brevet unitaire et juridiction unifiée du brevet
      • Validation nationale
      • Requête en extension/validation
    • Voie internationale (PCT)
      • Vue d'ensemble
      • Guide euro-PCT : procédure PCT devant l'OEB
      • Décisions et communiqués
      • Dispositions et ressources PCT
      • Requête en extension/validation
      • Programme de partenariat renforcé
      • Traitement accéléré des demandes PCT
      • Patent Prosecution Highway (PPH)
      • Formations et manifestations
    • Demandes nationales
    • Trouver un mandataire agréé
    • Services MyEPO
      • Vue d'ensemble
      • Comprendre nos services
      • Accéder aux services
      • Effectuer un dépôt
      • Intervenir sur un dossier
      • Disponibilité de services en ligne
    • Formulaires
      • Vue d'ensemble
      • Requête en examen
    • Taxes
      • Vue d'ensemble
      • Taxes européennes (CBE)
      • Taxes internationales (PCT)
      • Taxes du brevet unitaire
      • Paiements des taxes et remboursements
      • Avertissement

    up

    Découvrez comment le brevet unitaire peut améliorer votre stratégie de PI

  • Informations juridiques

    Informations juridiques

    Droit européen des brevets, Journal officiel et autres textes juridiques.

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • Textes juridiques
      • Vue d'ensemble
      • Convention sur le brevet européen
      • Journal officiel
      • Directives
      • Système d'extension/de validation
      • Accord de Londres
      • Droit national relatif à la CBE
      • Unitary patent system
      • Mesures nationales relatives au brevet unitaire
    • Pratiques juridictionnelles
      • Vue d'ensemble
      • Colloque des juges européens de brevets
    • Consultations d'utilisateurs
      • Vue d'ensemble
      • Consultations en cours
      • Consultations fermées
    • Harmonisation matérielle du droit des brevets
      • Vue d'ensemble
      • The Tegernsee process
      • Groupe B+
    • Convergence des pratiques
    • Options pour les mandataires agréés
    Image
    Law and practice scales 720x237

    Restez à jour des aspects clés de décisions choisies grâce à notre publication mensuelle "Abstracts of decisions”

  • Actualités et événements

    Actualités et événements

    Nos dernières actualités, podcasts et événements.

    Consulter la vue d'ensemble 

     

    • Vue d'ensemble
    • Actualités
    • Événements
    • Prix de l'inventeur européen
      • Vue d'ensemble
      • Ce que signifie demain
      • À propos du prix
      • Catégories et prix
      • Rencontrez les finalistes
      • Proposer un inventeur
      • European Inventor Network
      • La cérémonie 2024
    • Young Inventor Prize
      • Vue d'ensemble
      • À propos du prix
      • Appel à candidatures
      • Le jury
      • Le monde, réinventé
    • Centre de presse
      • Vue d'ensemble
      • Patent Index et statistiques
      • Recherche dans le centre de presse
      • Rappel des faits
      • Droits d'auteur
      • Contact presse
      • Demande de rappel
      • Service d'alerte par courriel
    • Coup de projecteur sur l'innovation et la protection par brevets
      • Vue d'ensemble
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Brevets et société
      • Technologies spatiales et satellitaires
      • L'avenir de la médecine
      • Science des matériaux
      • Communications mobiles
      • Brevets dans le domaine des biotechnologies
      • Patent classification
      • Technologies numériques
      • La fabrication de demain
      • Books by EPO experts
    • Podcast "Talk innovation"

    podcast

    De l’idée à l’invention : notre podcast vous présente les actualités en matière de technologies et de PI

  • Formation

    Formation

    L'Académie européenne des brevets – point d'accès pour vos formations

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • Activités de formation et parcours d'apprentissage
      • Vue d'ensemble
      • Activités de formation
      • Parcours d’apprentissage
    • EEQ et CEAB
      • Vue d'ensemble
      • EEQ – Examen européen de qualification
      • CEAB – Certificat européen d’administration des brevets
      • CSP – Programme de soutien aux candidats
    • Ressources par centre d'intérêt
      • Vue d'ensemble
      • Délivrance des brevets
      • Transfert et diffusion de technologies
      • Application des droits de brevet et contentieux en matière de brevets
    • Ressources de formation par profil
      • Vue d'ensemble
      • Entreprise et responsables PI
      • Candidats à l'EEQ et CEAB
      • Juges, juristes et parquets
      • Bureaux nationaux et autorités de PI
      • Conseils en brevets et assistants juridiques
      • Universités, centres de recherche et centre de transfert de technologie
    Image
    Patent Academy catalogue

    Un vaste éventail d’opportunités de formation dans le catalogue de l’Académie européenne des brevets

  • Découvrez-nous

    Découvrez-nous

    En savoir plus sur notre travail, nos valeurs, notre histoire et notre vision.

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • L'OEB en bref
    • Les 50 ans de la Convention sur le brevet européen
      • Vue d'ensemble
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Concours d’art collaboratif pour enfants
    • Fondements juridiques et États membres
      • Vue d'ensemble
      • Fondements juridiques
      • États membres de l'Organisation européenne des brevets
      • Etats autorisant l’extension
      • Etats autorisant la validation
    • Conseil d'administration et organes auxiliaires
      • Vue d'ensemble
      • Communiqués
      • Calendrier
      • Documentation
      • Le Conseil d'administration de l'Organisation européenne des brevets
    • Principes et stratégie
      • Vue d'ensemble
      • Mission, vision et valeurs
      • Plan stratégique 2028
      • Vers une nouvelle normalité
    • Présidence et Comité de direction
      • Vue d'ensemble
      • Président António Campinos
      • Comité consultatif de direction
    • Sustainability at the EPO
      • Vue d'ensemble
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services et activités
      • Vue d'ensemble
      • Nos services et notre structure
      • Qualité
      • Consultation de nos utilisateurs
      • Coopération européenne et internationale
      • Académie européenne des brevets
      • Économiste en chef
      • Bureau de médiation
      • Signaler des actes répréhensibles
    • Observatoire des brevets et des technologies
      • Vue d'ensemble
      • Acteurs de l'innovation
      • Politique et financement
      • Outils
      • À propos de l'Observatoire
    • Achats
      • Vue d'ensemble
      • Plan d’achats prévisionnel
      • La passation de marchés avec l'OEB
      • Procédures d'achat
      • Politique d'achat durable
      • Comment s‘enregistrer pour appels à la concurrence électroniques et signatures électroniques
      • Portail des achats
      • Facturation
      • Conditions générales
      • Appels à la concurrence archivés
    • Portail de transparence
      • Vue d'ensemble
      • Généralités
      • Capital humain
      • Capital environnemental
      • Capital organisationnel
      • Capital social et relationnel
      • Capital économique
      • Gouvernance
    • Statistics and trends
      • Vue d'ensemble
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • Historique de l'OEB
      • Vue d'ensemble
      • Années 1970
      • Années 1980
      • Années 1990
      • Années 2000
      • Années 2010
      • Années 2020
    • La collection d'art de l'OEB
      • Vue d'ensemble
      • La collection
      • Let's talk about art
      • Artistes
      • Médiathèque
      • What's on
      • Publications
      • Contact
      • Espace Culture A&T 5-10
      • "Longue nuit"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Suivez les dernières tendances technologiques grâce à notre Patent Index

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • Êtes-vous novice en matière de brevets ?
  • Êtes-vous novice en matière de brevets ?
    • Go back
    • Votre entreprise et les brevets
    • Pourquoi les brevets existent-ils ?
    • Quelle est votre grande idée ?
    • Êtes-vous prêts ?
    • Ce qui vous attend
    • Comment déposer une demande de brevet
    • Mon idée est-elle brevetable?
    • Êtes-vous le premier ?
    • Quiz sur les brevets
    • Vidéo sur le brevet unitaire
  • Recherche de brevets
    • Go back
    • Vue d'ensemble
    • Informations techniques
      • Go back
      • Vue d'ensemble
      • Espacenet - recherche de brevets
        • Go back
        • Vue d'ensemble
        • Bases de données des offices nationaux et régionaux
        • Global Patent Index (GPI)
        • Notes de version
      • Serveur de publication européen
        • Go back
        • Vue d'ensemble
        • Notes de version
        • Tableau de correspondance pour les demandes Euro-PCT
        • Fichier d’autorité EP
        • Aide
      • Recherche EP en texte intégral
    • Informations juridiques
      • Go back
      • Vue d'ensemble
      • Registre européen des brevets
        • Go back
        • Vue d'ensemble
        • Notes de version archive
        • Documentation sur le Registre
          • Go back
          • Vue d'ensemble
          • Couverture de données pour lien profonds
          • Registre fédéré
          • Événements du Registre
      • Bulletin européen des brevets
        • Go back
        • Vue d'ensemble
        • Télécharger les fichiers du Bulletin
        • Recherche dans le Bulletin EP
        • Help
      • Plan du site de l'Identifiant européen de la jurisprudence
      • Observations de tiers
    • Informations commerciales
      • Go back
      • Vue d'ensemble
      • PATSTAT
      • IPscore
        • Go back
        • Notes de version
      • Rapports d’analyse sur les technologies
    • Données
      • Go back
      • Vue d'ensemble
      • Technology Intelligence Platform
      • Données liées ouvertes EP
      • Jeux de données de masse
        • Go back
        • Vue d'ensemble
        • Manuals
        • Listages de séquences
        • Données nationales en texte intégral
        • Données du Registre européen des brevets
        • Données bibliographiques mondiale de l'OEB (DOCDB)
        • Données EP en texte intégral
        • Données mondiales de l'OEB relatives aux événements juridiques (INPADOC)
        • Données bibliographiques EP (EBD)
        • Décisions des chambres de recours de l'OEB
      • Services Internet
        • Go back
        • Vue d'ensemble
        • Services brevets ouverts (OPS)
        • Serveur de publication européen (service web)
      • Couverture, codes et statistiques
        • Go back
        • Mises à jour hebdomadaires
        • Mises à jour régulières
    • Plateformes technologiques
      • Go back
      • Le plastique en pleine mutation
        • Go back
        • Overview
        • Récupération des déchets plastiques
        • Recyclage des déchets plastiques
        • Matières plastiques de substitution
      • Vue d'ensemble
      • L'innovation dans les technologies de l'eau
        • Go back
        • Overview
        • Eau salubre
        • Protection contre l'eau
      • Innovation spatiale
        • Go back
        • Vue d'ensemble
        • Astronautique
        • Observation spatiale
      • Des technologies pour lutter contre le cancer
        • Go back
        • Vue d'ensemble
        • Prévention et détection précoce
        • Diagnostics
        • Thérapies
        • Bien-être et suivi
      • Technologies de lutte contre les incendies
        • Go back
        • Vue d'ensemble
        • Détection et prévention des incendies
        • Extinction des incendies
        • Matériel de protection
        • Technologies de restauration après incendie
      • Technologies énergétiques propres
        • Go back
        • Vue d'ensemble
        • Énergies renouvelables
        • Industries à fortes émissions de carbone
        • Stockage de l’énergie et autres technologies complémentaires
      • Lutte contre le coronavirus
        • Go back
        • Vue d'ensemble
        • Vaccins et thérapies
          • Go back
          • Overview
          • Vaccins
          • Aperçu des traitements candidats contre la Covid-19
          • Antiviral et traitement symptomatique candidats
          • Acides nucléiques et anticorps de lutte contre le coronavirus
        • Diagnostics et analyses
          • Go back
          • Vue d'ensemble
          • Diagnostics - essais basés sur une protéine ou un acide nucléique
          • Protocoles analytiques
        • Informatique
          • Go back
          • Vue d'ensemble
          • Bioinformatique
          • Informatique médicale
        • Les technologies de la nouvelle normalité
          • Go back
          • Vue d'ensemble
          • Appareils, matériel et équipements
          • Procédures, actions et activités
          • Technologies numériques
        • Les inventeurs en lutte contre le coronavirus
    • Ressources utiles
      • Go back
      • Vue d'ensemble
      • Il s'agit de votre première visite ? Qu'est-ce que l'information brevets ?
        • Go back
        • Vue d'ensemble
        • Définitions de base
        • Classification des brevets
          • Go back
          • Vue d'ensemble
          • Classification coopérative des brevets (CPC)
        • Familles de brevets
          • Go back
          • Vue d'ensemble
          • Famille de brevets simple DOCDB
          • Famille de brevets élargie INPADOC
        • À propos des événements juridiques
          • Go back
          • Vue d'ensemble
          • Système de classification INPADOC
      • Information brevets de l'Asie
        • Go back
        • Vue d'ensemble
        • China (CN)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Taipei Chinois (TW)
          • Go back
          • Vue d'ensemble
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Inde (IN)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japon (JP)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Corée (KR)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Fédération de Russie (RU)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Centres d'information brevets (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Commerce et statistiques
      • Informations relatives au brevet unitaire pour la connaissance des brevets
  • Demander un brevet
    • Go back
    • Vue d'ensemble
    • Voie européenne
      • Go back
      • Vue d'ensemble
      • Guide du brevet européen
      • Oppositions
      • Procédure orale
        • Go back
        • Calendrier des procédures orales
          • Go back
          • Accès du public à la procédure de recours
          • Accès du public à la procédure d’opposition
          • Calendrier des procédures orales
          • Directives techniques
      • Recours
      • Brevet unitaire et juridiction unifiée du brevet
        • Go back
        • Brevet unitaire
          • Go back
          • Vue d'ensemble
          • Cadre juridique
          • Principales caractéristiques
          • Comment obtenir un brevet unitaire
          • Coût d'un brevet unitaire
          • Traduction et compensation
          • Date de début
          • Introductory brochures
        • Vue d'ensemble
        • Juridiction unifiée du brevet
      • National validation
      • Requête en extension/validation
    • Demandes internationales
      • Go back
      • Vue d'ensemble
      • Guide euro-PCT
      • Entrée dans la phase européenne
      • Décisions et communiqués
      • Dispositions et ressources PCT
      • Requête en extension/validation
      • Programme de partenariat renforcé
      • Traitement accéléré des demandes PCT
      • Patent Prosecution Highway (PPH)
        • Go back
        • Programme Patent Prosecution Highway (PPH) – Présentation
      • Formations et manifestations
    • Voie nationale
    • Services MyEPO
      • Go back
      • Overview
      • Comprendre nos services
        • Go back
        • Vue d'ensemble
        • Exchange data with us using an API
          • Go back
          • Notes de version
      • Accéder aux services
        • Go back
        • Vue d'ensemble
        • Notes de version
      • Effectuer un dépôt
        • Go back
        • Effectuer un dépôt
        • Que faire si nos services de dépôt en ligne sont indisponibles ?
        • Notes de version
      • Intervenir sur un dossier
        • Go back
        • Notes de version
      • Disponibilité de services en ligne
    • Taxes
      • Go back
      • Vue d'ensemble
      • Taxes européennes (CBE)
        • Go back
        • Vue d'ensemble
        • Décisions et communiqués
      • Taxes internationales (PCT)
        • Go back
        • Réduction des taxes
        • Taxes pour les demandes internationales
        • Décisions et communiqués
        • Vue d'ensemble
      • Taxes du brevet unitaire
        • Go back
        • Vue d'ensemble
        • Décisions et avis
      • Paiements des taxes et remboursements
        • Go back
        • Vue d'ensemble
        • Modes de paiement
        • Premiers pas
        • FAQs et autre documentation
        • Informations techniques concernant les paiements groupés
        • Décisions et communiqués
        • Notes de version
      • Avertissement
    • Formulaires
      • Go back
      • Requête en examen
      • Vue d'ensemble
    • Trouver un mandataire agréé
  • Informations juridiques
    • Go back
    • Vue d'ensemble
    • Textes juridiques
      • Go back
      • Vue d'ensemble
      • Convention sur le brevet européen
        • Go back
        • Vue d'ensemble
        • Archive
          • Go back
          • Vue d'ensemble
          • Documentation sur la révision de la CBE en 2000
            • Go back
            • Vue d'ensemble
            • Conférence diplomatique pour la révision de la CBE
            • Travaux préparatoires
            • Nouveau texte
            • Dispositions transitoires
            • Règlement d'exécution de la CBE 2000
            • Règlement relatif aux taxes
            • Ratifications et adhésions
          • Travaux Préparatoires CBE 1973
      • Journal officiel
      • Directives
        • Go back
        • Vue d'ensemble
        • Directives CBE
        • Directives PCT de l'OEB
        • Directives relatives au brevet unitaire
        • Cycle de révision des directives
        • Consultation results
        • Résumé des contributions des utilisateurs
        • Archive
      • Système d'extension/de validation
      • Accord de Londres
      • Droit national relatif à la CBE
        • Go back
        • Vue d'ensemble
        • Archive
      • Système du brevet unitaire
        • Go back
        • Travaux préparatoires to UP and UPC
      • Mesures nationales relatives au brevet unitaire
    • Pratiques juridictionnelles
      • Go back
      • Vue d'ensemble
      • Colloque des juges européens de brevets
    • Consultations d'utilisateurs
      • Go back
      • Vue d'ensemble
      • Consultations en cours
      • Consultations fermées
    • Harmonisation matérielle du droit des brevets
      • Go back
      • Vue d'ensemble
      • The Tegernsee process
      • Groupe B+
    • Convergence des pratiques
    • Options pour les mandataires agréés
  • Actualités et événements
    • Go back
    • Vue d'ensemble
    • Actualités
    • Événements
    • Prix de l'inventeur européen
      • Go back
      • The meaning of tomorrow
      • Vue d'ensemble
      • À propos du prix
      • Catégories et prix
      • Découvrir les inventeurs
      • Proposer un inventeur
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • La cérémonie 2024
    • Young Inventors Prize
      • Go back
      • Vue d'ensemble
      • À propos du prix
      • Appel à candidatures
      • Le jury
      • The world, reimagined
      • La cérémonie 2025
    • Centre de presse
      • Go back
      • Vue d'ensemble
      • Patent Index et statistiques
      • Recherche dans le centre de presse
      • Rappel des faits
        • Go back
        • Vue d'ensemble
        • L'Office européen des brevets
        • Questions/réponses sur les brevets en lien avec le coronavirus
        • Questions/réponses sur les brevets portant sur des végétaux
      • Droits d'auteur
      • Contact presse
      • Formulaire - Demande de rappel
      • Service d'alerte par courriel
    • Coup de projecteur
      • Go back
      • Vue d'ensemble
      • Technologies liées à l'eau
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Vue d'ensemble
        • CodeFest 2024 sur l'IA générative
        • CodeFest 2023 sur les plastiques verts
      • Green tech in focus
        • Go back
        • Vue d'ensemble
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Brevets et société
      • Technologies spatiales et satellitaires
        • Go back
        • Brevets et technologies spatiales
        • Vue d'ensemble
      • L'avenir de la médecine
        • Go back
        • Vue d'ensemble
        • Technologies médicales et cancer
        • Personalised medicine
      • Science des matériaux
        • Go back
        • Vue d'ensemble
        • Nanotechnologie
      • Communications mobiles
      • Biotechnologie
        • Go back
        • Biotechnologies rouges, blanches ou vertes
        • Vue d'ensemble
        • Rôle de l’OEB
        • Inventions brevetables
        • Les inventeurs dans le domaine des biotechnologies
      • Classification
        • Go back
        • Vue d'ensemble
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Vue d'ensemble
          • External partners
          • Updates on Y02 and Y04S
      • Technologies numériques
        • Go back
        • Vue d'ensemble
        • A propos des TIC
        • Matériel et logiciel
        • Intelligence artificielle
        • Quatrième révolution industrielle
      • Fabrication additive
        • Go back
        • Vue d'ensemble
        • À propos de la FA
        • Innover avec la FA
      • Books by EPO experts
    • Podcast
  • Formation
    • Go back
    • Vue d'ensemble
    • Activités de formation et parcours d'apprentissage
      • Go back
      • Vue d'ensemble
      • Activités de formation : types et formats
      • Parcours d’apprentissage
    • EEQ et CEAB
      • Go back
      • Vue d'ensemble
      • EEQ – Examen européen de qualification
        • Go back
        • Vue d'ensemble
        • Compendium
          • Go back
          • Vue d'ensemble
          • Épreuve F
          • Épreuve A
          • Épreuve B
          • Épreuve C
          • Épreuve D
          • Examen préliminaire
        • Candidats reçus
        • Archives
      • CEAB – Certificat européen d’administration des brevets
      • CSP – Programme de soutien aux candidats
    • Ressources de formation par centre d'intérêt
      • Go back
      • Vue d'ensemble
      • Délivrance des brevets
      • Transfert et diffusion de technologies
      • Application des droits de brevet et contentieux en matière de brevets
    • Ressources de formation par profil
      • Go back
      • Vue d'ensemble
      • Enterprises et responsables IP
        • Go back
        • Vue d'ensemble
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • Études de cas : technologies à forte croissance
        • Inventor's handbook
          • Go back
          • Vue d'ensemble
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Vue d'ensemble
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Vue d'ensemble
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • Candidats à l'EEQ et CEAB
        • Go back
        • Vue d'ensemble
        • Casse-têtes sur l'épreuve F
        • Questions D quotidiennes
        • Examen européen de qualification - Guide de préparation
        • CEAB
      • Juges, juristes et parquets
        • Go back
        • Vue d'ensemble
        • Compulsory licensing in Europe
        • Compétences des juridictions européennes pour les litiges en matière de brevets
      • Offices nationaux et administrations de la PI
        • Go back
        • Vue d'ensemble
        • Parcours d'apprentissage pour les examinateurs de brevets des offices nationaux
        • Parcours d'apprentissage pour agents des formalités et assistants juridiques
      • Conseils en brevets et assistants juridiques
      • Universités, centres de recherche et Offices de Transfert Technologique
        • Go back
        • Vue d'ensemble
        • Cadre modulaire d'enseignement de la propriété intellectuelle (MIPEF)
        • Programme de stages professionnels "Pan-European Seal"
          • Go back
          • Vue d'ensemble
          • Pour les étudiants
          • Pour les universités
            • Go back
            • Vue d'ensemble
            • Ressources éducatives sur la propriété intellectuelle
            • Adhésion universitaire
          • Nos jeunes professionnel(le)s
          • Programme de développement professionnel
        • Programme de recherche académique (ARP)
          • Go back
          • Vue d'ensemble
          • Projets de recherche finalisés
          • Projets de recherche en cours
        • Kit d'enseignement sur la PI
          • Go back
          • Vue d'ensemble
          • Télécharger des modules
        • Manuel de conception de cours sur la propriété intellectuelle
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • Initiative sur le transfert de connaissances vers l'Afrique (KT2A)
          • Activités fondamentales dans le cadre de l'initiative KT2A
          • Jumelage réussi dans le cadre de l'initiative KT2A : le centre PATLIB de Birmingham et l'université des sciences et technologies du Malawi
  • Découvrez-nous
    • Go back
    • Vue d'ensemble
    • L'OEB en bref
    • Les 50 ans de la CBE
      • Go back
      • Official celebrations
      • Vue d'ensemble
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Concours d’art collaboratif pour enfants
    • Fondements juridiques et États membres
      • Go back
      • Vue d'ensemble
      • Fondements juridiques
      • Etats membres
        • Go back
        • Vue d'ensemble
        • Etats membres selon la date d'adhésion
      • Etats autorisant l’extension
      • Etats autorisant la validation
    • Conseil d'administration et organes auxiliaires
      • Go back
      • Vue d'ensemble
      • Communiqués
        • Go back
        • 2024
        • Vue d'ensemble
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendrier
      • Documentation
        • Go back
        • Vue d'ensemble
        • Documents du Comité restreint
      • Conseil d'administration
        • Go back
        • Vue d'ensemble
        • Composition
        • Représentants
        • Règlement intérieur
        • Collège des commissaires aux comptes
        • Secrétariat
        • Organes
    • Principes et stratégie
      • Go back
      • Vue d'ensemble
      • Mission, vision et valeurs
      • Plan stratégique 2028
        • Go back
        • Levier 1 : Les personnes
        • Levier 2 : Les technologies
        • Levier 3 : Des produits et services de grande qualité
        • Levier 4 : Les partenariats
        • Levier 5 : La pérennité financière
      • Vers une nouvelle normalité
      • Protection des données et confidentialité
    • Présidence et Comité de direction
      • Go back
      • Vue d'ensemble
      • A propos du Président
      • Comité consultatif de direction
    • La pérennité à l'OEB
      • Go back
      • Overview
      • Pérennité environnementale
        • Go back
        • Overview
        • Inventions environnementales inspirantes
      • Pérennité sociale
        • Go back
        • Overview
        • Inventions sociales inspirantes
      • Gouvernance et pérennité financière
    • Achats
      • Go back
      • Vue d'ensemble
      • Plan d’achats prévisionnel
      • La passation de marchés avec l'OEB
      • Procédures d'achat
      • Publications du système d'acquisition dynamique
      • Politique d'achat durable
      • Sur appels à la concurrence électroniques
      • Facturation
      • Portail des achats
        • Go back
        • Vue d'ensemble
        • Signature électronique des contrats
      • Conditions générales
      • Appels à la concurrence archivés
    • Services et activités
      • Go back
      • Vue d'ensemble
      • Nos services et notre structure
      • Qualité
        • Go back
        • Vue d'ensemble
        • Fondements
          • Go back
          • Vue d'ensemble
          • La Convention sur le brevet européen
          • Directives relatives à l'examen
          • Notre personnel
        • Comment stimuler la qualité
          • Go back
          • Vue d'ensemble
          • État de la technique
          • Système de classification
          • Outils
          • Des procédés gages de qualité
        • Produits et services
          • Go back
          • Vue d'ensemble
          • Recherches
          • Examens
          • Oppositions
          • Amélioration continue
        • La qualité grâce au travail en réseau
          • Go back
          • Vue d'ensemble
          • Engagement des utilisateurs
          • Coopération
          • Enquêtes visant à évaluer le degré de satisfaction
          • Groupes de parties prenantes sur l'assurance de la qualité
        • Charte sur la qualité des brevets
        • Plan d'action pour la qualité
        • Quality dashboard
        • Statistiques
          • Go back
          • Vue d'ensemble
          • Recherche
          • Examen
          • Opposition
        • Gestion intégrée à l'OEB
      • Consultation de nos utilisateurs
        • Go back
        • Vue d'ensemble
        • Comité consultatif permanent auprès de l'OEB
          • Go back
          • Vue d'ensemble
          • Objectifs
          • Le SACEPO et ses groupes de travail
          • Réunions
          • Espace délégués
        • Enquêtes
          • Go back
          • Vue d'ensemble
          • Méthodologie détaillée
          • Services de recherche
          • Services d'examen, actions finales et publication
          • Services d'opposition
          • Services de Formalités
          • Service clientèle
          • Services de dépôt
          • Gestion des grands comptes
          • Site web de l'OEB
          • Archives
      • Notre charte du service clientèle
      • Coopération européenne et internationale
        • Go back
        • Vue d'ensemble
        • Coopération avec les Etats membres
          • Go back
          • Vue d'ensemble
        • Coopération bilatérale avec les États non membres
          • Go back
          • Vue d'ensemble
          • Le système de validation
          • Programme de partenariat renforcé
        • Organisations internationales, coopération tripartite et IP5
        • Coopération avec les organisations internationales en dehors du système de PI
      • Académie européenne des brevets
        • Go back
        • Vue d'ensemble
        • Partenaires
      • Économiste en chef
        • Go back
        • Vue d'ensemble
        • Études économiques
      • Bureau de l'Ombud
      • Signaler des actes répréhensibles
    • Observatoire des brevets et des technologies
      • Go back
      • Vue d'ensemble
      • Technologies
        • Go back
        • Vue d'ensemble
        • Innovation contre le cancer
        • Robotique d'assistance
        • Technologies spatiales
      • Acteurs de l'innovation
        • Go back
        • Vue d'ensemble
        • Start-ups et PME
          • Go back
          • Publications
      • Politique et financement
        • Go back
        • Vue d'ensemble
        • Programme de financement de l'innovation
          • Go back
          • Vue d'ensemble
          • Nos études sur le financement de l'innovation
          • Initiatives de l'OEB pour les demandeurs de brevet
          • Soutien financier pour les innovateurs en Europe
        • Brevets et normes
          • Go back
          • Vue d'ensemble
          • Publications
          • Patent standards explorer
      • Outils
        • Go back
        • Vue d'ensemble
        • Deep Tech Finder
      • À propos de l'Observatoire
        • Go back
        • Vue d'ensemble
        • Programme de travail
    • Transparency portal
      • Go back
      • Vue d'ensemble
      • Généralités
        • Go back
        • Vue d'ensemble
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Vue d'ensemble
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Capital humain
      • Capital environnemental
      • Capital organisationnel
      • Capital social et relationnel
      • Capital économique
      • Gouvernance
    • Statistics and trends
      • Go back
      • Vue d'ensemble
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • Historique
      • Go back
      • Vue d'ensemble
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Collection d'art
      • Go back
      • Vue d'ensemble
      • La collection
      • Let's talk about art
      • Artistes
      • Médiathèque
      • What's on
      • Publications
      • Contact
      • Espace Culture A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Expositions précédentes
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Longue nuit"
  • Chambres de recours
    • Go back
    • Vue d'ensemble
    • Décisions des chambres de recours
      • Go back
      • Décisions récentes
      • Vue d'ensemble
      • Sélection de décisions
    • Communications des chambres de recours
    • Procédure
    • Procédures orales
    • À propos des chambres de recours
      • Go back
      • Vue d’ensemble
      • Président des chambres de recours
      • Grande Chambre de recours
        • Go back
        • Vue d’ensemble
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Chambres de recours techniques
      • Chambre de recours juridique
      • Chambre de recours statuant en matière disciplinaire
      • Praesidium
        • Go back
        • Vue d’ensemble
    • Code de conduite
    • Plan de répartition des affaires
      • Go back
      • Vue d’ensemble
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Liste annuelle des affaires
    • Communications
    • Rapport annuel
      • Go back
      • Vue d’ensemble
    • Publications
      • Go back
      • Résumés des décisions
    • La Jurisprudence des Chambres de recours
      • Go back
      • Vue d'ensemble
      • Archive
  • Service et ressources
    • Go back
    • Vue d'ensemble
    • Mises à jour du site Internet
    • Disponibilité de services en ligne
      • Go back
      • Vue d'ensemble
    • FAQ
      • Go back
      • Vue d'ensemble
    • Publications
    • Commande
      • Go back
      • Connaissances des Brevets - Produits et Services
      • Vue d'ensemble
      • Conditions générales
        • Go back
        • Vue d'ensemble
        • Produits d'informations brevets
        • Donnés brutes
        • Services brevets ouverts (OPS)
        • Charte d'utilisation équitable
    • Notifications relatives aux procédures
    • Liens utiles
      • Go back
      • Vue d'ensemble
      • Offices des brevets des Etats membres
      • Autres offices des brevets
      • Répertoires de conseils en propriété industrielle
      • Bases de données, registres et gazettes des brevets
      • Disclaimer
    • Centre d'abonnement
      • Go back
      • Vue d'ensemble
      • S'abonner
      • Gérer ses préférences
      • Se désabonner
    • Contactez-nous
      • Go back
      • Vue d'ensemble
      • Options de dépôt
      • Localisations
    • Jours fériés
    • Glossaire
    • Flux RSS
Board of Appeals
Decisions

Recent decisions

Vue d'ensemble
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Accueil
  2. Node
  3. T 2562/18 21-07-2020
Facebook X Linkedin Email

T 2562/18 21-07-2020

Identifiant européen de la jurisprudence
ECLI:EP:BA:2020:T256218.20200721
Date de la décision
21 July 2020
Numéro de l'affaire
T 2562/18
Requête en révision de
-
Numéro de la demande
11153847.6
Classe de la CIB
A61M1/36
Langue de la procédure
EN
Distribution
NO DISTRIBUTION (D)

Téléchargement et informations complémentaires:

Décision en EN 726.53 KB
Les documents concernant la procédure de recours sont disponibles dans le Registre européen des brevets
Informations bibliographiques disponibles en:
EN
Versions
Non publié
Titre de la demande

Citrate anticoagulation system for extracorporeal blood treatments

Nom du demandeur
Nikkiso Co., Ltd.
Nom de l'opposant

B. Braun Avitum AG

Fresenius Medical Care AG & Co. KGaA

Chambre
3.2.02
Sommaire
-
Dispositions juridiques pertinentes
European Patent Convention 054(1) (2007)
European Patent Convention 054(2) (2007)
European Patent Convention 056 (2007)
European Patent Convention 076(1) (2007)
European Patent Convention 084 (2007)
European Patent Convention 100(b) (2007)
European Patent Convention 123(2) (2007)
Mot-clé

Grounds for opposition - insufficiency of disclosure (no)

Novelty - main request (no)

Novelty - auxiliary request 2 (yes)

Claims - clarity

Claims - auxiliary requests 1 and 2 (yes)

Amendments - extension beyond the content of the original

application and the parent application as filed - auxiliary

request 1 (yes) - auxiliary request 2 (no)

Inventive step - auxiliary request 2 (yes)

Exergue
-
Décisions citées
T 0404/16
Décisions dans lesquelles la présente décision est citée
T 0404/16

Summary of Facts and Submissions

I. The patent proprietor and the opponents have appealed against the Opposition Division's decision, posted on on 18 September 2018, that, account being taken of the amendments according to auxiliary request 1 then on file, European patent No. 2 324 871 and the invention to which it related met the requirements of the EPC.

The patent is derived from a divisional application of European patent application No. 06 838 361.1 ("the parent application"), which is the object of appeal case T 404/16. It was opposed on the grounds of added subject-matter, insufficient disclosure, exception to patentability, lack of novelty and lack of inventive step.

II. Oral proceedings took place on 21 July 2020.

The appellant/patent proprietor ("the proprietor") requested that the decision under appeal be set aside and the patent be maintained on the basis of the main request filed on 13 September 2017 or, as an auxiliary measure, on the basis of one of auxiliary requests 1 to 5 filed with letter dated 16 May 2019.

The appellants/opponents ("the opponents") requested that the decision under appeal be set aside and the patent be revoked.

III. The following documents are mentioned in the present decision:

D2: WO-A-2004/069311

D2a: US-A-2005/0011823

D10: US-A-5,910,252

D11: US-A-2005/0085760

D11a: WO-A-2005/039671

D31: US-A-4,500,309

D32: "Gebrauchsanweisung Automatischer Akutbilanzmonitor AQUARIUS - Für Platinum Software Version 4", Edwards Lifesciences, May 2004

IV. Claims 1, 7 and 9 of the main request read as follows:

"1. A machine-readable storage medium embodying instructions that may be performed by one or more processors, the instructions comprising:

instructions for pumping blood from a patient's blood stream into an access line (1);

instructions for introducing an anticoagulant solution into the pumped blood;

instructions for filtering the pumped blood;

instructions for delivering the pumped blood from the filtering step to a return line (2);

instructions for returning the blood back to the patient's blood stream;

instructions for introducing a calcium solution into the filtered blood traveling through the return line (2), wherein the calcium solution includes magnesium

characterized by

instructions for introducing a substitution fluid from a supply of substitution fluid (11) into the pumped blood traveling through the access line (1) using a first pump (23) coupled to the access line (1);

instructions for introducing the substitution fluid from the supply of substitution fluid (11) into the filtered blood traveling through the return line (2) using a second pump (50) coupled to the return line (2)."

"7. The machine-readable storage medium according to any one of the preceding claims, further comprising:

instructions for detecting air bubbles from the blood introduced with the substitution fluid; and

instructions for removing air bubbles from the blood before it is returned into the patient's blood stream."

"9. The machine-readable storage medium according to any one of the preceding claims, wherein the substitution fluid is a dialysis solution."

Claim 1 of auxiliary request 1 reads as follows (amendments over claim 1 of the main request highlighted by the Board):

"A machine-readable storage medium embodying instructions that may be performed by one or more processors, the instructions comprising:

instructions for pumping blood from a patient's blood stream into an access line (1) by the driving force of a blood pump (14);

instructions for introducing an anticoagulant solution into the pumped blood by an anticoagulant pump (24);

instructions for filtering the pumped blood;

instructions for delivering the pumped blood from the filtering step to a return line (2);

instructions for returning the blood back to the patient's blood stream;

instructions for introducing a calcium solution into the filtered blood traveling through the return line (2), wherein the calcium solution includes magnesium

characterized by

instructions for introducing a substitution fluid from a supply of substitution fluid (11) into the pumped blood traveling through the access line (1) using a first pump (23) coupled to the access line (1);

instructions for introducing the substitution fluid from the supply of substitution fluid (11) into the filtered blood traveling through the return line (2) using a second pump (50) coupled to the return line (2);

instructions for, when one pump halts for any reason, stopping the pumping of the other pumps, wherein the stops of blood pump (14) and anticoagulant pump (24) are delayed after the other pumps have stopped."

Claim 1 of auxiliary request 2 reads as follows (amendments over claim 1 of auxiliary request 1 highlighted by the Board):

"A machine-readable storage medium embodying instructions that may be performed by one or more processors, the instructions comprising:

instructions for controlling a blood pump (14), a filtrate pump (8), a first post-dilution pump (50), a pre-dilution pump (23), a dialysate pump, an anticoagulant pump (24) and a second post-dilution pump (16);

instructions for pumping blood from a patient's blood stream into an access line (1) by the driving force of [deleted: a] the blood pump (14);

instructions for introducing an anticoagulant solution into the pumped blood by [deleted: an] the anticoagulant pump (24);

instructions for filtering the pumped blood;

instructions for delivering the pumped blood from the filtering step to a return line (2);

instructions for returning the blood back to the patient's blood stream;

instructions for introducing a calcium solution into the filtered blood traveling through

the return line (2) by the second post-dilution pump (16), wherein the calcium solution includes magnesium

characterized by

instructions for introducing a substitution fluid from a supply of substitution fluid (11) into the pumped blood traveling through the access line (1) using [deleted: a first pump] the pre-dilution pump (23) coupled to the access line (1);

instructions for introducing the substitution fluid from the supply of substitution fluid (11) into the filtered blood traveling through the return line (2) using [deleted: a second pump] the first post-dilution pump (50) coupled to the return line (2);

instructions for, when one pump halts for any reason, stopping the pumping of the other pumps, wherein the stops of blood pump (14) and anticoagulant pump (24) are delayed after the other pumps have stopped."

Claims 2 to 9 are dependent claims. Claims 7 and 9 read as claims 7 and 9 of the main request.

V. The proprietor's arguments, where relevant to the present decision, may be summarised as follows:

Main request - Sufficiency of disclosure

Claim 1 of the main request was directed to a storage medium embodying instructions for performing method steps involving the conveyance of fluids in a blood treatment machine. The patent disclosed the technical means employed for carrying out those method steps. In particular, the steps of filtering the pumped blood, delivering the pumped blood to the return line and returning the blood back to the patient's blood stream were carried out by the cooperation of appropriately regulated pumps of the machine. The claimed instructions contained specific information about the respective method steps. In particular, they contained information about the fluid to be conveyed. How to formulate the specific instructions for conveying the specific fluids, taking into account their nature, such that the instruction could suitably be employed in an algorithm for an electronic control unit of the blood treatment machine, was within the competence of the person skilled in the art of software development.

Claim 7 did not require that air bubbles were differentiated with regard to their origin. Air bubbles introduced with the substitution fluid were detected and removed. If air bubbles having other origins were present, they would also be detected and removed.

Claim 9 defined the nature of a fluid to be conveyed in the blood treatment machine. How to formulate specific instructions for suitably conveying this fluid was within the competence of the person skilled in the art of software development.

Main request - novelty

The subject-matter of claim 1 of the main request was novel over D2/D2a and D11/D11a.

These documents did not disclose the administration of a calcium solution including magnesium. The presence or absence of magnesium in the calcium solution had a direct impact on the electrolyte balance of the patient. The presence of magnesium compensated for a part of the magnesium removed in the filtration fluid and allowed to fully restore the patient's electrolyte balance to a physiological state. Instructions for adding calcium solution containing magnesium had to contain very specific information about the solution that was conveyed. Hence, they were different from those needed if the calcium solution did not contain magnesium.

D2/D2a and D11/D11a did not disclose either that the two pumps for introducing substitution fluid pumped from the same fluid supply, as specified in claim 1. Introducing fluid with two pumps from a single supply required different instructions which had to take into account the properties of the supply, such as the quantity of fluid present in the supply.

Auxiliary request 1 - added subject-matter

In claim 1, the feature "instructions for, when one pump halts for any reason, stopping the pumping of the other pumps, wherein the stops of blood pump (14) and anticoagulant pump (24) are delayed after the other pumps have stopped" was based on paragraph [0056] of the application as filed. The claim had to be understood to imply that the calcium solution was delivered by a pump, as shown in particular in Figures 3 and 4 of the patent. The patent did not teach that the calcium solution could be delivered by any means other than a pump. Even if such a pump were not implied by the claim wording, the person skilled in the art would understand the claim wording to mean that the supply of calcium solution was stopped when one pump of the blood treatment machine stopped for any reason.

In the written proceedings the following arguments were also raised:

A basis for claiming a machine readable storage medium was present in paragraph [0067] of the parent application and paragraph [0068] of the application as filed.

The general definition of substitution fluid administered from the same supply in claim 1, without specifying that the fluid did not include calcium and magnesium ions, did not amount to an unallowable intermediate generalisation. Claims 2 and 3 of the application as filed generally disclosed a substitution fluid without specifying its nature. Whether this fluid was taken from one single supply had no technical relationship with the ion content of the fluid.

The features regarding pre- and post-dilution were not disclosed only in connection with hemofiltration in the application as filed. There was no strict separation between hemofiltration and other blood treatments, as derivable in particular from paragraphs [0043], and [0051] of the application as filed. Accordingly, paragraph [0055] of the application as filed disclosed that the pre- and post-dilution were the same dialysate - i.e. dialysis - solution, which could be employed for any of the disclosed blood treatments, including hemofiltration. It followed that claim 1 and claim 9 did not contain any added subject-matter in this respect.

Auxiliary request 2 - Novelty and inventive step

D2/D2a and D11/D11a did not disclose that when one pump halted for any reason the blood pump and the anticoagulant pump were stopped with a delay after the other pumps had already stopped. D10, D31 and D32 did not show this feature either.

By providing that all other pumps stop, but the stops of the blood pump and the anticoagulant pump are delayed, the return line and the return catheter were allowed to fill with blood containing citrate. This avoided clotting, as explained in paragraph [0056] of the application as filed. In turn, this addressed the objective technical problem on increasing patient safety.

It followed that the subject-matter of claim 1 of auxiliary request 2 was novel and inventive.

VI. The opponents' arguments, where relevant to the present decision, may be summarised as follows:

Main request - Sufficiency of disclosure

The invention as defined in claims 1 and 9 was not sufficiently disclosed, since it was not possible to provide instructions in a storage medium which, alone, made it possible to deliver a specific solution. It was not disclosed how, on the basis of the instructions, the machine for carrying them out could recognise the nature of the solution to be administered. Providing such instructions went beyond the normal competence of the person skilled in the art.

The patent did not disclose the specific technical means employed for carrying out the instructions for filtering the pumped blood, delivering it to a return line and returning it to the patient. These steps were simply a result of a method of treatment carried out by a blood treatment machine, and did not involve any individual technical means for receiving those instructions. It was therefore not possible to put the instructions into practice.

The subject-matter of claim 7 was not sufficiently disclosed either. In particular, it was not disclosed how the origin of the air bubbles present in the blood could be determined. Moreover, the air trap for removing air bubbles disclosed in the patent functioned without any control by an electronic unit. It was therefore not possible to put into practice the instructions defined in claim 7.

Main request - novelty

The subject-matter of claim 1 of the main request was not novel over D2/D2a and D11/D11a.

Each of these documents disclosed the administration of an electrolyte solution which could contain calcium and/or magnesium. The instructions for operating a pump intended to deliver such a solution did not depend on the specific nature of the solution, in particular whether the electrolyte solution contained magnesium in addition to calcium or not. The pump could not recognise the solution pumped.

D2/D2a and D11/D11a also disclosed instructions for introducing substitution fluid into the blood travelling through the access line and into the blood travelling through the return line. It was irrelevant, as far as the nature of the instructions was concerned, whether the substitution fluid was drawn from a single container or from two distinct containers.

Auxiliary request 1 - added subject-matter

The feature "instructions for, when one pump halts for any reason, stopping the pumping of the other pumps, wherein the stops of blood pump (14) and anticoagulant pump (24) are delayed after the other pumps have stopped" had been extracted from paragraph [0055] of the parent application as filed. However, this paragraph contained other features omitted from the claim, such as the features that all pumps were controlled together and that all pumps had to run if the blood pump was running. Hence, a further unallowable intermediate generalisation was present.

According to claim 1 the administration of the calcium solution, which was not necessarily performed by a pump, did not have to stop before the stop of the blood pump and the anticoagulant pump. However, the parent application as filed taught that this was the case in order to avoid clotting during the halting of the blood pump (paragraph [0055] of the parent application as filed). Omitting this feature in claim 1 amounted to an unallowable intermediate generalisation.

In the written procedure the opponents also raised the following points:

The term "storage medium" employed in paragraph [0067] of the parent application as filed was in relation to the specific embodiments. Its introduction into claim 1 amounted to an unallowable intermediate generalisation.

The parent application as filed taught (paragraph [0048]) that the substitution fluid did not include calcium and magnesium ions. Omitting this information in claim 1 amounted to an unallowable intermediate generalisation.

The embodiments depicted in Figures 3 and 4 of the parent application as filed were hemofiltration devices. Omitting this definition in claim 1 was not allowable, since the subject-matter of the claim extended to other blood treatment devices. Such a generalisation had no basis in the parent application as filed.

The features recited in claim 9 were based on paragraph [0054] of the parent application as filed, which related to a dialysis system. Such a system had nothing to do with the hemofiltration devices of the embodiments of Figures 3 and 4, on which the claimed machine-readable medium was based. Hence, there was no basis for the combination of the features recited in claim 9 with those of claim 1. Moreover, only some of the features of the combination disclosed in paragraph [0054] had been claimed. This amounted to a further unallowable generalisation.

Auxiliary request 2 - Novelty and inventive step

D2/D2a and D11/D11a anticipated all the features of claim 1 of auxiliary request 2 except the last feature concerning the stopping of the pumps when one pump halted for any reason. This last feature concerned the handling of malfunctions, and was in no technical relation to the other features of the claim, which generally concerned the layout of a blood treatment system. In such a case it was the established case law that the combination of more documents could prejudice the novelty of the claim. D10, column 17, lines 21 to 30 and column 19, lines 52 to 62 disclosed a condition of malfunction of a blood treatment system in which the pumps were stopped as claimed. Even if those passages did not explicitly mention the stop of an anticoagulant pump, while the blood pump was still running, this was implicit for the person skilled in the art. The combination of the teaching of D10 with the disclosure of D2/D2a or D11/D11a deprived the subject-matter of claim 1 of novelty.

The combination of D2/D2a or D11/D11a with D10 and/or D31 rendered obvious the subject-matter of claim 1 in view of the problem of ensuring the safety of the patient when one pump stopped working. D31 additionally taught that in a blood treatment system an anticoagulant pump containing citrate should be shut down after a period of time following the shut down of the blood pump (column 5, lines 30 to 42) in order to full the return line with blood and anticoagulant to avoid the risk of clotting.

In the written procedure the opponents also submitted the following arguments:

Also the combination of D2/D2a or D11/D11a with D32 rendered obvious the subject-matter of claim 1. According to page 29, point 3.6, of D32 the actuation of a button "Behandlung Start/Stop" interrupted a blood treatment by stopping a filtration pump, a pre-dilution pump and a post-dilution pump, while a blood pump continued running. Since page 30 disclosed that for the stopping of an anticoagulant pump the option "Spritzenwechsel" was foreseen, implicitly the anticoagulant pump continued running together with the blood pump upon actuation of the button "Behandlung Start/Stop". Hence, D32 disclosed the distinguishing feature of claim 1 with respect to D2/D2a or D11/D11a.

The subject-matter of claim 1 of auxiliary request 2 was not inventive when starting from D32. This document disclosed all the claim features except the administration of a calcium solution containing magnesium by the means of a pump. The administration by a pump of such an electrolyte solution was however known from several documents of the state of the art and did not involve an inventive step in view of the problem of optimising the electrolyte balance in the patient's blood.

Reasons for the Decision

1. The invention

The invention relates to a machine-readable storage medium embodying instructions relating to a blood treatment therapy.

Such a therapy could be a Continuous Renal-Replacement Therapy (CRRT), indicated for critically ill patients. CRRT is a kind of slow and continuous dialysis therapy, which is better tolerated than the traditional dialysis as it does not involve sudden changes in the blood which may cause cardiovascular instability. Continuous Veno-Venous Hemofiltration (CVVH), Continuous Arterio-Venous Hemofiltration (CAVH), Continuous Veno-Arterial Hemofiltration (CVAH), Continuous-VenoVenous-Hemo-DiaFiltration (CVVHD or CVVHDF) and Continuous-Arterio-VenousHemo-DiaFiltration (CAVHD or CAVHDF), mentioned in paragraphs [0003] and [0004] of the patent are all special kinds of CRRT.

The instructions defined in claim 1 of the main request may be carried out, according to the patent, by an extracorporeal blood treatment system as schematically depicted in Figures 3 and 4 reproduced below.

FORMULA/TABLE/GRAPHIC

FORMULA/TABLE/GRAPHIC

The instructions comprise instructions for pumping blood from a patient into an access line (access line 1, by means of blood pump 14), introducing an anticoagulant solution into the blood (at inlet port 32, by means of anticoagulant pump 24), filtering the blood (in artificial kidney 60), delivering the blood to a return line (return line 2, from artificial kidney 60) and then back to the patient, introducing a calcium solution including magnesium into the filtered blood traveling through the return line (at connection 46, by means of second post-dilution pump 16), introducing a substitution fluid into the blood using a first pump coupled to the access line (via pre-dilution line 31, by means of pre-dilution pump 23), and introducing the substitution fluid into the blood also using a second pump coupled to the return line (via post-dilution line 52, by means of first post-dilution pump 50).

The introduction of the substitution fluid and the calcium solution are intended to supplement the blood in order to compensate the loss of liquid and other constituents due to the filtration process and possibly to promote that process (substitution fluid introduced in the access line). Controlling the administration of all these fluids is important so as not to have those sudden changes in the patient's blood, which make traditional dialysis not suitable for critically ill patients.

Claim 1 of auxiliary request 2 additionally specifies, in particular, that the anticoagulant solution and the calcium solution are to be introduced by respective pumps, and defines instructions for, when one pump halts for any reason, stopping the pumping of the other pumps, wherein the stops of the blood pump and the anticoagulant pump are delayed after the other pumps have stopped.

According to the patent (paragraph [0055]) this is done to fill the return line with blood containing anticoagulant, to avoid the risk of clotting inside this line when the blood is not circulating.

2. Main request - sufficiency of disclosure

2.1 Claim 1 of the patent as granted is directed to a storage medium embodying instructions for performing certain method steps to be carried out by an electronically controlled blood treatment system.

2.2 What the claim requires is the suitability of such instructions for carrying out the respective method steps by means of a blood treatment system appropriately set up for this purpose. In other terms, there is no claim requirement that the instructions should enable the system to distinguish between possible fluids to be conveyed. Still, when the conveyance of a certain fluid is referred to, the instructions should enable the conveyance of this specific fluid in view of the technical purpose of the blood treatment system, i.e. the performance of a suitable treatment of a patient. For example, the instructions for introducing an anticoagulant solution into the pumped blood should enable the introduction of such a solution from a source, the source being present in the system, at a time and at a flow rate which make it effective in the treatment without putting at risk the patient's health. These time and flow rate are well known to the person skilled in the art from the common general knowledge.

2.3 As the proprietor submitted, the patent discloses the technical means of an electronically controlled blood treatment system adapted to carry out the method steps defined in claim 1 on the basis of appropriate software instructions. These are, in particular, the pumps of the system as depicted in Figures 3 and 4. The opponents' argument that for some instructions - i.e. for filtering the pumped blood, delivering it to a return line and returning it to the patient - this was not the case is not convincing. It can be accepted that the patent may not disclose a single physical entity, such as a dedicated pump, for carrying out each of the claimed instructions. Still, each instruction may be carried out by the blood treatment system as a whole, in certain cases by the cooperation of more than one element of the system. For example, the delivery of blood to a return line with a system as depicted in Figure 3 will depend on the flow rates of blood pump 14, pre-dilution pump 23 and filtration pump 8, which can be controlled by specific instructions.

2.4 Hence, the Board concludes that the person skilled in the art can readily formulate the instructions for the respective purposes as defined in claim 1 on the basis of the disclosure of the patent (in particular paragraphs [0058] to [0062]) and the common general knowledge.

2.5 For the same reasons, also the instructions defined in claim 9 can readily be formulated by the person skilled in the art.

2.6 As far as claim 7 is concerned, the opponents argued that the removal of air by the means of air traps 3 (Figure 4) worked without any control from a CPU. However, the patent additionally teaches that air can be removed with the aid of an air bubble detector (33) controlled by a monitoring system (paragraph [0052]). This amounts to a disclosure of a technical means adapted to carry out the method step defined in claim 7, on the basis of appropriate software instructions.

The opponents further argued that the patent did not disclose how to distinguish between air bubbles introduced with the substitution fluid and air bubbles of another origin. However, claim 7 simply defines instructions for detecting air bubbles introduced with the substitution fluid, without distinguishing the origin of the bubbles. Detecting all air bubbles (as taught in the patent) will inevitably detect the air bubbles introduced with the substitution fluid.

2.7 It follows that the ground for opposition of insufficient disclosure (Article 100(b) EPC) does not prejudice the maintenance of the patent on the basis of the main request.

3. Main request - novelty

The opponents argued on the basis of documents D2, D2a, D11 and D11a. D2 and D2a belong to the same patent family and have the same technical content. The same applies to D11 and D11a. For ease of reference the Board will only refer to D2a and D11 in the following.

3.1 D2a concerns a system that can be employed for performing hemofiltration in intensive therapy (paragraphs [0002] and [0010]). Such a system is schematically depicted in Figure 1 reproduced below.

FORMULA/TABLE/GRAPHIC

D2a discloses an access line (3a) with a blood pump (21), an anticoagulant syringe (35) for introducing an anticoagulant into the blood, a blood filter (2), a return line (3b), a pump (9) suitable for introducing a calcium solution into the blood (paragraphs [0149] to [0151]), a pump (19) for introducing substitution fluid from a supply of substitution fluid into the blood traveling through the access line (paragraphs [0046] and [0047]) and a further pump (13) for introducing substitution fluid from another supply of substitution fluid into the blood traveling through the return line (paragraph [0075]).

These elements are controlled by a processing unit (40, paragraph [0105]). It follows that the system of D2a must comprise a machine readable medium (RAM or ROM) comprising suitable instructions for the processing unit.

The proprietor argued that D2a did not disclose the administration of a calcium solution including magnesium. The Board agrees. D2a generally discloses the administration of an electrolyte solution containing "suitable substances (for instance calcium) for recovering the ion balance in the blood" when citrates are used as anticoagulants (paragraph [0149]).

However, claim 1 merely requires instructions suitable for introducing a generically defined "calcium solution including magnesium". In the absence of a more precise definition of the solution, for example the respective concentrations of calcium and magnesium, the Board concludes that instructions for introducing an electrolyte solution of the kind mentioned in D2a at times and at a flow rate which make the administration effective in the treatment without putting at risk the patient's health will also be suitable for administering, for the same purpose, an electrolyte solution according to the definition of claim 1. As a matter of fact, the description of the patent does not describe either how the claimed instruction could possibly differ from an instruction for introducing a calcium solution as known from D2a.

The proprietor also argued that D2a did not disclose two pumps for introducing substitution fluid which pumped from the same fluid supply.

However, this is irrelevant as far as the nature of the instructions suitable for introducing the substitution fluid are concerned. The time and the flow rate of the administration do not depend on where the fluid comes from, but are only related to the administration means, in particular pumps 19 and 13 of D2a.

The Board therefore concludes that D2a discloses all the features of claim 1 of the main request.

3.2 D11 concerns a system that can be employed for performing hemofiltration in the context of CRRT (paragraph [0035]). Such a system is schematically depicted in Figure 3 reproduced below.

FORMULA/TABLE/GRAPHIC

D11 discloses an access line (102) with a blood pump (112), an anticoagulant pump (120), a blood filter (140), a return line (104), a pump (32) suitable for introducing an electrolyte solution into the blood (paragraph [0058]), a substitution pump (114a) for introducing substitution fluid from a supply of substitution fluid into the blood traveling through the access line (paragraph [0056]), and a substitution pump (114b) for introducing substitution fluid from another supply of substitution fluid into the blood traveling through the return line (paragraphs [0055] and [0056]).

These elements are controlled by a processing unit (70, Figure 2). It follows that the system of D11 must comprise a machine readable medium (RAM or ROM) comprising suitable instructions for the processing unit.

Pump 32 is suitable for administering a calcium and magnesium solution into the blood: paragraph [0018] discloses that infusions of calcium and magnesium (specific electrolyte solutions) can be administered, and paragraph [0058], discloses that pump 32, coupled to supply 156, can be used to administer, inter alia, electrolyte solutions.

Contrary to the proprietor's view, for the same reasons as those given with respect to D2a, D11 also anticipates instructions suitable for introducing a generically defined calcium solution including magnesium into the filtered blood traveling through the return line as required by claim 1.

For the reasons explained in view of D2a the fact that D11 does not disclose two pumps introducing substitution fluid which pump from the same fluid supply does not represent a differentiating feature either.

It follows that the subject-matter of claim 1 of the main request also lacks novelty in view of D11.

3.3 As a consequence, the patent cannot be maintained on the basis of the main request for lack of novelty (Article 54(1) and (2) EPC).

4. Auxiliary request 1 - added subject-matter

Claim 1 of auxiliary request 1 is based mainly on claim 1 of the original application and claim 34 of the parent application as filed, in combination with page 17, lines 18 to 29, of the original application and paragraph [0055] of the parent application as filed as regards the feature "instructions for, when one pump halts for any reason, stopping the pumping of the other pumps, wherein the stops of blood pump (14) and anticoagulant pump (24) are delayed after the other pumps have stopped".

4.1 The definition of the machine-readable medium being a "storage medium" is based on paragraph [0067] of the parent application and page 21, lines 4 to 16 of the original application as filed. These passages expressly refer to "the methods or algorithms described in connection with the embodiments disclosed herein". Hence they constitute a general disclosure for all the embodiments of the invention. It follows that the opponents' argument regarding an alleged intermediate generalisation in this respect is without merit.

4.2 A basis for the definition that the substitution fluid introduced before and after the blood filter is the same fluid is provided by claims 2 and 3 of the original application and claims 35 and 36 of the parent application as filed, and by Figure 3 of the parent and the original application as filed. The Board does not accept the opponents' argument that it should be specified that this substitution fluid does not contain calcium and magnesium ions. Those claims of the original application and the parent application as filed did not specify it either. The presence or absence of calcium and magnesium ions in the substitution fluids is in no technical relation to issue of whether one or more of such fluids is used.

4.3 The opponents' argument concerning the absence of the definition that the instructions are for carrying out hemofiltration is not convincing for similar reasons. Claim 1 of the original application and claim 34 of the parent application as filed did not require it either. The use of a single substitution fluid or the specific instructions concerning the stopping of the pumps cannot make this definition necessary, from a technical point of view.

4.4 The additional features of claim 9 are based on paragraph [0054] of the parent application and page 17, lines 15 to 17 of the original application as filed. Contrary to the opponents' submissions, these passages are not specific to dialysis devices, but concern the nature of the substitution fluids, and the pumps and tubing employed in any of the disclosed blood treatment systems. There is thus no inextricable link between the specific nature of the fluids mentioned in these passages and the means for their administration. Hence, the opponents' objection of added subject-matter directed to claim 9 is not convincing.

4.5 However, the introduction of the feature "instructions for, when one pump halts for any reason, stopping the pumping of the other pumps, wherein the stops of blood pump (14) and anticoagulant pump (24) are delayed after the other pumps have stopped" in claim 1 of auxiliary request 1 is problematic.

The opponents argued that it constituted an unallowable intermediate generalisation, in particular because claim 1 did not specify that all pumps were controlled together, that when the blood pump run all other pumps had to be activated, and that the administration of the solution containing calcium and magnesium had to stop before the stop of the blood pump and the anticoagulant pump.

As regards the allegedly omitted feature that all pumps are controlled together, this is implied by the claim on a technical reading of it. The claimed instructions, when implemented, result in the stop of all the pumps. This implies their control.

Claim 1 of the original application and claim 34 of the parent application as filed did not prescribe that when the blood pump runs all other pumps have to be activated. Moreover, this feature is clearly not inextricably linked with the claimed delay of the stop of the anticoagulant pump and the blood pump, which is for preventing clogging of the return line when the system stops (paragraph [0055] of the parent application and page 17, lines 18 to 29 of the original application as filed). It follows that its omission does not add subject-matter.

However, as the opponents argued, the omission of the feature that the administration of the solution containing calcium and magnesium should stop before the stop of the blood pump and the anticoagulant pump is not allowable. If that administration is not stopped the prevention of the risk of clogging the return line, which is what the claimed instructions aim at, is not achieved: free calcium ions, which play an important role in the coagulation of blood and which are bound by the anticoagulant, would be re-introduced into the blood. Hence, the original application and the parent application as filed inextricably link the omitted feature with the claimed instructions of stopping the pumps. In contrast, claim 1 of auxiliary request 1 conveys the information that the stopping of the administration of the solution containing calcium and magnesium is merely optional.

The proprietor's argument that claim 1 of auxiliary request 1 had to be understood to imply that the administration of the solution containing calcium and magnesium should stop before the stop of the blood pump and the anticoagulant pump is not convincing. The claim does simply not state that such administration is performed by means of a pump. Moreover, a pump is not the only possible technical means for performing that administration. The solution could be delivered from an infusion bag by gravity or from a reservoir under pressure, whereby the flow rate could be controlled by a regulating valve, for example. Hence, stopping the pumps does not necessarily result in stopping the administration of the solution containing calcium and magnesium.

4.6 For this reason the subject-matter of claim 1 of auxiliary request 1 extends beyond the content of the original application and the parent application as filed, in contravention of Articles 76(1) and 123(2) EPC.

Hence

5. Auxiliary request 2 - Article 123(2), 83 and 84 EPC

In claim 1 of auxiliary request 2 it is expressly mentioned that the calcium solution including magnesium is administered by a pump, i.e. the second post-dilution pump. Hence, the claimed instructions for stopping all the pumps of the system imply that the administration of this solution stops before the stop of the blood pump and the anticoagulant pump. This overcomes the non-compliance with Articles 76(1) and 123(2) EPC explained above.

For the reasons given in the analysis of the main request made above, auxiliary request 2 also meets the requirements of sufficiency of disclosure.

6. Auxiliary request 2 - Novelty and inventive step

It is common ground that D2/D2a and D11/D11a do not disclose instructions for, when one pump halts for any reason, stopping the pumping of the other pumps, wherein the stops of blood pump and anticoagulant pump are delayed after the other pumps have stopped.

6.1 The opponents argued that since this distinguishing feature concerned a technical problem which was different from the problem addressed by the other claim features a combination of more documents could prejudice the novelty of the claim.

It is the established jurisprudence that, in the assessment of novelty, the claimed invention should be compared with the prior art to see whether the invention differs from it. If it does, no matter for which reason, the invention is novel. In the comparison it is not permissible to combine separate items of prior art together. A claimed subject-matter would lack novelty only if a "clear and unmistakable teaching" of a combination of the claimed features could be found in a prior art disclosure (Case Law of the Boards of Appeal of the European Patent Office, Ninth Edition, July 2019, I.C.4.2 and I.C.5.1).

It follows that the opponents' objection of lack of novelty based on the combination of separate documents (D2/D2a or D11/D11a with D10) is without merit.

6.2 The opponents argued against inventive step starting from D2/D2a or D11/D11a, in combination with one or more of D10, D31 and D32.

D2/D2a and D11/D11a do not disclose instructions for, when one pump halts for any reason, stopping the pumping of the other pumps, wherein the stops of blood pump and anticoagulant pump are delayed after the other pumps have stopped.

As the proprietor submitted, the patent (paragraph [0055]) explains that this distinguishing feature allows to fill the return line with blood containing anticoagulant, to avoid the risk of clotting inside this line when the blood is not circulating.

This solves the objective technical problem of increasing the safety of a patient under treatment, in case the treatment is continued after the stop of all pumps.

6.2.1 D10 (column 17, lines 25 to 30) discloses a "safe state" of an extracorporeal blood treatment apparatus in which all pumps of the apparatus are stopped. Column 19, lines 52 to 57, discloses that a control processor puts the apparatus in the "safe state" if a pump is malfunctioning. According to column 19, lines 57 to 64, if the malfunction is detected "the operator may choose [...] to disconnect the patient with or without returning treated blood to the patient". The opponents argued that this implied that the blood pump had to run longer than the other pumps before being eventually stopped so as to reach the "safe state". Even if this were accepted, there is no disclosure in D10, either explicit or implicit, that the anticoagulant pump should continue running together with the blood pump. The Board notes that D10 is silent about any risk of blood clotting for the purpose of returning the treated blood to the patient before disconnection. This risk is not implicit either, since during that operation the blood would circulate normally in the blood treatment apparatus. It follows that D10 does not disclose the distinguishing feature. It is not concerned with the objective technical problem either.

6.2.2 D31 concerns a system for performing hemodialysis employing citrate as an anticoagulant (column 3, lines 5 to 12). In column 4, lines 57 to 68, D31 teaches that the system should be monitored to ensure that citrate and calcium ions are being added during the hemodialysis operation and that the blood pump should be monitored with the dialyser for determining if and when the blood is bypassing the dialyser. Column 5, lines 30 to 42, mentioned by the opponents, concerns this last situation. It discloses:

"the calcium ion pump should be shut down immediately whereas the blood pump should be shut down only after a delay of, e.g., 3 minutes. This permits sufficient time to adjust the dialyzer apparatus without shutting the entire apparatus [...] down. This for the reason that bypass operations are relatively common, and a patient would be in no danger for a short period while attempts are made to put the dialyzer apparatus back on stream. In addition, the citrate pump should be shut down after a period of time following shut down of the blood pump, e.g., 4 minutes after monitoring of a bypass condition in the dialyzer".

Hence, D31 does not disclose instructions for, when one pump halts for any reason, stopping the pumping of the other pumps. In fact, it suggests that the bypass condition is relatively common and should be solved without the need of a complete stop of the system. Moreover, D31 does not teach to fill the return line with blood containing anticoagulant in order to solve the objective technical problem, but simply to purge it altogether by leaving the anticoagulant pump in operation after the blood pump has stopped. It follows that D31 does also not suggest that the objective technical problem should be addressed as it is done by the claimed invention.

6.2.3 D32 concerns a system for CRRT, in particular hemofiltration, comprising, inter alia, a blood pump and an anticoagulant pump (page 9). On page 29, referred to by the opponents, it is explained that pressing a button "Behandlung Start/Stop" activates a function of the system in which a pre-dilution pump, a post-dilution pump and a filtrate pump are stopped while the blood pump continues working. On page 30, also referred to by the opponents, it is disclosed that a syringe containing an anticoagulant can be replaced activating a further function of the system. This implies an interruption of the administration of the anticoagulant. However, there is no disclosure in D32 that these functions are in any relation to each other. In particular, there is simply no disclosure in D32 that the anticoagulant delivery can only be interrupted by activating the function of the syringe replacement or that when the function "Behandlung Start/Stop" is activated the anticoagulant syringe continues delivering anticoagulant. Hence, D32 does not disclose the distinguishing feature of claim 1 of auxiliary request 2. It does not address the objective technical problem either.

6.2.4 Since none of D10, D31 and D32 teaches the distinguishing feature for the solution of the objective technical problem, their combination with D2/D2a or D11/D11a does not render obvious the subject-matter of claim 1.

6.3 The opponents also argued against inventive step of claim 1 of auxiliary request 2 starting from D32, under the assumption that this document disclosed all the claim features except the administration of a calcium solution containing magnesium by the means of a pump, and that this feature was rendered obvious by several other documents of the state of the art.

However, as explained above, D32 does not disclose the claimed instructions for stopping the pumps either.

It follows that the objection starting from D32 is without merit for this reason alone.

6.4 In conclusion, the subject-matter of claim 1 of auxiliary request 2 - and a fortiori of dependent claims 2 to 9 - is novel (Article 54(1) and (2) EPC) and inventive (Article 56 EPC).

Dispositif

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the Opposition Division with the order to maintain the patent as amended in the following version:

- claims: 1-9 according to auxiliary request 2 filed with letter dated 16 May 2019;

- description: pages 2, 4-7, 9 of the patent specification, and pages 3 and 8 filed during the oral proceedings before the Opposition Division on 2 July 2018;

- drawings: Figures 1-6 of the patent specification.

Footer - Service & support
  • Soutien
    • Mises à jour du site Internet
    • Disponibilité de services en ligne
    • FAQ
    • Publications
    • Notifications relatives aux procédures
    • Contact
    • Centre d'abonnement
    • Jours fériés
    • Glossaire
Footer - More links
  • Centre de presse
  • Emploi et carrière
  • Single Access Portal
  • Achats
  • Chambres de recours
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Adresse bibliographique
  • Conditions d’utilisation
  • Protection des données
  • Accessibilité